ALKS

Alkermes plc.

7 filings tracked

healthcarebiotechnologyMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition

90%

bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise

70%

bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression

60%

bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat

75%

bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition

90%

bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise

70%

bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression

60%

bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat

75%

bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition

90%

bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise

70%

bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression

60%

bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat

75%

bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition

90%

bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise

70%

bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression

60%

bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat

75%

bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition

90%

bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise

70%

bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression

60%

bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat

75%

bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition

90%

bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise

70%

bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression

60%

bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat

75%

bullishMay 5

Acquired Avadel Pharmaceuticals for $2.3B, adding LUMRYZ and a narcolepsy commercial organization.

acquisition

90%

bearishMay 5

Increased long-term debt by $1.525 billion to fund the Avadel acquisition.

capital raise

70%

bearishMay 5

Operating income swung to a loss due to acquisition costs and inventory step-up amortization.

margin compression

60%

bullishMay 5

Total revenues grew 28% YoY, driven by strong performance in LYBALVI and ARISTADA.

earnings beat

75%

Filing History

10-QMay 5, 2026

The Q1 2026 filing reveals a company in the midst of a high-stakes transformation. By aggressively leveraging its balance sheet to acquire Avadel, Alkermes has traded short-term profitability and cash reserves for long-term strategic positioning in the sleep medicine market. The immediate revenue jump is promising, but the transition has introduced substantial debt service obligations and accounting complexities that mask the true operational margin. Investors are now faced with a classic biotech trade-off: the certainty of increased leverage and short-term losses versus the potential for blockbuster returns from LUMRYZ and the Alixorexton pipeline. The success of this transition will likely depend on the speed of LUMRYZ's commercial ramp-up and the outcome of the Phase 3 Brilliance Studies. Until these catalysts materialize, the stock will likely remain sensitive to interest rate fluctuations and the resolution of its ongoing intellectual property litigation.